Healthcare Industry News: LifeScan
News Release - September 26, 2011
Easton Pharmaceuticals Strengthens Sales Capabilities With Key Management Team AdditionJohn Mitchell, Noted Pharmaceutical Sales and Marketing Professional, Accepts Position as Vice President of Sales-North America
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network)- Easton Pharmaceuticals, (Pinksheets: EAPH.PK ) a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that John Mitchell has agreed to join the company as Vice President of Sales - North America. Mr. Mitchell brings years of pharmaceutical sales and marketing experience to compliment Easton Pharmaceuticals management team.
Mr. Mitchell has more than 30 years of sales and marketing experience, holding V.P. of Sales positions for several leading North American pharmaceutical and consumer products companies. Mitchell developed and implemented contract agreements for consumer promotions and OEM products for Bayer, Roche Diagnostics, Eli Lilly, Abbott, Medisense, and LifeScan, a division of J&J.
"We are extremely pleased to have a seasoned professional like John Mitchell join our team and lead our sales efforts," stated John Easton, Easton Pharmaceuticals' CEO and Chairman of the Board. "John will be a key member of our management team as Easton Pharmaceuticals opens new markets and distribution networks for our future product lines."
As Vice President of Sales - North America, Mr. Mitchell will create and direct key sales and marketing programs, including direct to consumer and direct response marketing plans from product sourcing, packaging, label and product claim review, and full retail sales and marketing support. Mr Mitchell will be leveraging his extensive sales channel contacts to help Easton Pharmaceuticals build key retail bridges to all major U.S and Canadian retailers, include CVS, Walgreens, GNC, Wal-Mart plus many other retail outlets.
About Easton Pharmaceuticals Inc.
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete and secure additional or adequate financing and other risks and uncertainties as listed in the company's financial reports and filings.
Source: Easton Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.